Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.

Anticancer research - 1 Jan 2000

Hartikainen Jaana M, Mannermaa Arto, Heinonen Seppo, Kosma Veli-Matti, Kataja Vesa

Abstract excerpt

BACKGROUND: Mutations in the BRCA1/2 genes confer a high risk for breast and ovarian cancer, with usually adverse clinical characteristics. The clinical course and response to treatment in mutation carriers have been reported infrequently and are assumed to be worse than in sporadic breast cancer. PATIENTS AND METHODS: Eleven members of an Eastern Finnish family with multiple cases of breast and ovarian cancers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Finland
Share to Genes, BRCA2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Haplotypes

Share to Heterozygote

Share to Ovarian Neoplasms

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 18214034

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.PMID 18214034Read ↗

BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer.Semantic proximity Read ↗

Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.Semantic proximity Read ↗

Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.Semantic proximity Read ↗

BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.Semantic proximity Read ↗

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.Semantic proximity Read ↗

Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.Semantic proximity Read ↗

Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer.Semantic proximity Read ↗

Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition.Semantic proximity Read ↗

Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.Semantic proximity Read ↗

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.Semantic proximity Read ↗

BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer.Semantic proximity Read ↗

G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.